Europe Personalized Medicine Market Report

Europe Personalised Medicine Market Size

The Europe personalised medicine market size was valued at USD 168.32 billion in 2024 and is projected to reach USD 348.43 billion by 2033 from USD 182.49 billion in 2025, growing at a CAGR of 8.42%.

Personalised medicine in Europe refers to the tailoring of medical treatment and prevention strategies to individual patient characteristics, including genomic profiles, biomarker expression, lifestyle factors, and environmental exposures. This paradigm shifts healthcare from a reactive, population-based model to a proactive, precision-driven approach that enhances therapeutic efficacy while minimising adverse effects. The European Union has institutionalised this transition through policy frameworks such as the Europe’s Beating Cancer Plan and the 1+ Million Genomes Initiative, which aim to enable cross-border access to genomic and health data for clinical decision-making. As per Eurostat, more than 60% of Europeans aged 65 and older live with at least two chronic conditions, creating a compelling clinical need for targeted therapies.

MARKET DRIVERS

Integration of Genomic Data into National Healthcare Systems

The systematic incorporation of genomic sequencing and biomarker testing into publicly funded healthcare pathways is a primary driving factor for the growth of the European personalised medicine market. National initiatives have moved beyond pilot projects to routine clinical implementation, particularly in oncology. According to the Organisation for Economic Co-operation and Development, 19 European countries now reimburse next-generation sequencing panels for advanced non-small cell lung cancer by enabling treatment selection based on EGFR, ALK, or ROS1 status. In the United Kingdom, the National Health Service launched the Genomic Medicine Service in 2018, which by 2024 had delivered over 500000 whole genome sequences for diagnostic and therapeutic purposes as per NHS England. As per the European Reference Network on Genetic Tumour Risk Syndromes, standardised genomic workflows have reduced time to targeted therapy initiation across participating centres

Rising Prevalence of Complex Chronic and Oncologic Diseases

The escalating burden of cancers and treatment-resistant chronic conditions is intensifying demand for therapies that align with individual molecular profiles is accelerating the growth of the European personalised medicine market. Cancer alone accounts for 2.7 million new cases annually in the EU, according to the International Agency for Research on Cancer, with significant heterogeneity even within single tumour types. For instance, breast cancer is now classified into at least four molecular subtypes, each requiring distinct therapeutic approaches. According to the European Centre for Disease Prevention and Control, the number of patients eligible for gene-targeted therapies in Europe has been growing rapidly over the past few years. This clinical reality compels health systems to adopt companion diagnostics and molecular tumour boards, which are making personalised medicine not optional but essential for effective disease management in an era of biological complexity.

MARKET RESTRAINTS

Fragmented Reimbursement Policies Across Member States

The scalability of personalized medicine in Europe from the lack of harmonized reimbursement criteria for genomic tests and targeted therapies across national borders is solely limiting the growth of Europe personalized medicine market. According to the European Observatory on Health Systems and Policies, the time to achieve reimbursement for a companion diagnostic ranges from 60 days in Germany to over 400 days in Italy. As per the Personalised Medicine Coalition Europe, this inconsistency creates market access delays and discourages diagnostic manufacturers from launching pan-European tests.

Limited Interoperability of Health Data Infrastructure

The practical exchange of genomic and clinical data across European healthcare systems by incompatible digital infrastructures and inconsistent data standards is limiting the growth of the European personalised medicine market. The leaving countries are reliant on disparate electronic health record formats and laboratory information systems. According to the European Institute for Innovation and Technology, fewer than 15 EU member states have achieved semantic interoperability between genomic databases and hospital records as of 2024. In Germany, for example, genomic data generated in university hospitals often cannot be linked to longitudinal treatment outcomes due to legacy IT systems. As per the European Society of Human Genetics, only a few clinical genomics centres routinely share variant interpretations across borders, which is limiting the statistical power needed to interpret rare mutations.

MARKET OPPORTUNITIES

Expansion of the European Health Data Space for Cross-Border Genomic Research

The operational rollout of the European Health Data Space to promote secure, standardised access to federated health datasets is likely to set up new opportunities for the growth of Europe's personalised medicine market. Once fully implemented, this framework will enable researchers and clinicians to query anonymised genomic and clinical records across member states while preserving data sovereignty. According to the European Commission, the initial phase will connect national genomic repositories from 18 countries by 2026 by covering over 2 million sequenced individuals. The infrastructure will also support decentralised clinical trials, allowing patients to participate based on molecular eligibility rather than geographic proximity.

Adoption of AI-Driven Clinical Decision Support Systems

The integration of artificial intelligence into clinical workflows to translate complex genomic data into actionable treatment recommendations at the point of care is certainly to escalate the growth of Europe's personalised medicine market. The hospitals are increasingly deploying AI platforms that synthesise genomic variants, pathology images, and electronic health records to suggest evidence-based therapies. The FinnGen project uses machine learning to link genomic data from 500000 citizens with national health registries, which is identifying novel drug response predictors for cardiovascular disease. AI-based decision support tools received CE marking for oncology applications. These systems address the shortage of bioinformaticians and molecular pathologists; only 11 EU countries meet the WHO-recommended ratio of one genomic specialist per 200000 people.

MARKET CHALLENGES

Workforce Shortage in Genomic Medicine and Bioinformatics

The delivery of personalised medicine is the acute scarcity of professionals trained in genomic interpretation, molecular pathology, and clinical bioinformatics, which is challenging the growth of Europe's personalised medicine market. According to the European Society of Human Genetics, the EU faces a shortfall of over 8000 certified clinical geneticists and 12000 bioinformaticians needed to support current genomic testing volumes. The consequence is delayed reporting, underutilization of available tests, and reliance on external laboratories that may not integrate findings into local care pathways.

Ethical and Legal Ambiguities Surrounding Secondary Genomic Findings

The handling of incidental or secondary findings from genomic sequencing, such as predispositions to untreatable neurodegenerative diseases, is another challenge for the growth of Europe's personalised medicine market. National guidelines vary widely on whether and how to report such results. As per the European Commission’s Group of Advisors on the Ethical Implications of Biotechnology, 41% of European patients decline genomic testing due to fear of unanticipated results. Furthermore, data protection authorities remain divided on whether genomic data used for secondary research constitutes identifiable information under the General Data Protection Regulation.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Product Insights

The personalised medicine diagnostics segment accounted in holding 58.3% of the European personalised medicine market share in 2024, with the foundational role of diagnostic tools in enabling targeted therapy selection in oncology and rare diseases. The national health systems have responded by embedding genomic testing into standard care. According to the European Society for Medical Oncology, the use of molecular profiling increased the therapy response rate when compared to empirical treatment in non-small cell lung cancer. Furthermore, the EU’s In Vitro Diagnostic Regulation, fully applicable since 2022, has elevated quality standards by fostering trust in diagnostic accuracy.

Personalised medicine diagnostics segment is expected to grow with an anticipated CAGR of 12.4% from 2025 to 2033, with the expanding scope of genomic applications beyond oncology into neurology, cardiology, and pharmacogenomics. The technological advances further fuel adoption with Illumina’s NovaSeq X platform, deployed in 14 European reference labs by early 202, which reduced whole genome sequencing costs to under 200 euros per sample. Additionally, the rollout of the European Health Data Space enables real-world validation of diagnostic biomarkers across populations, accelerating clinical uptake.

REGIONAL ANALYSIS

Germany Market Analysis

Germany was the top performer in the European personalised medicine market with 26.3% of share in 2024, with its robust research infrastructure, early adoption of genomic medicine in statutory health insurance, and strong industrial base in diagnostics and biotechnology. Statutory health insurers reimburse comprehensive next-generation sequencing panels, and the Federal Joint Committee has established standardised evaluation criteria for companion diagnostics. Germany also hosts key players like Qiagen and Siemens Healthineers, which drive innovation in liquid biopsy and AI-assisted image analysis. The nation excels in translating biomarker discovery into clinical protocols, which is making it the most advanced and scalable personalised medicine ecosystem in Europe.

United Kingdom Market Analysis

The United Kingdom was ranked second by holding 21.3% of the European personalised medicine market in 2024. The UK’s pioneering role in the world’s first national genomic healthcare service, established in 2018, which has sequenced over 500000 whole genomes by 2024. The National Health Service embeds genomic testing into routine pathways for cancer, rare diseases, and infectious disease surveillance, with results delivered through a network of seven Genomic Laboratory Hubs. The NHS also mandates molecular tumour boards for all advanced cancer cases by ensuring multidisciplinary interpretation of complex data.

France Market Analysis

France personalised medicine market growth is likely to grow with significant growth opportunities during the forecast period, with a centralised national genomics strategy and strong public research institutions. France also leads in pharmacogenomics implementation; the Haute Autorité de Santé recommends HLA B*5701 screening before abacavir prescription, which prevents hypersensitivity in over 25000 patients annually. Additionally, France actively participates in EU initiatives like the 1+ Million Genomes project and the European Health Data Space pilot by ensuring cross-border data utility.

Italy Market Analysis

Italy's personalised medicine market growth is likely to grow steadily in the coming years, with the regional innovation hubs and national effortsstandardisinge genomic testing in oncology. The non-small cell lung cancer, colorectal cancer, and melanoma, with reimbursement guaranteed under the Essential Levels of Care framework, as per the Ministry of Health. Lombardy and Tuscany lead in adopting liquid biopsy for therapy monitoring, with over 15000 tests performed annually as per regional health authority data. Italy also participates in the European Reference Networks for rare diseases and cancer, facilitating case sharing and diagnostic harmonisation.

COMPETITIVE LANDSCAPE

KEY MARKET PLAYERS

Some of the notable key players in the European personalised medicine market are

• Genelux Corp
• Exagen Inc Ordinary Shares
• Danaos Corp
• Genentech
• 23andMe Holding Co Class A
• Biogen Inc
• Asure Software Inc
• Exact Sciences Corp
• Qiagen NV
• Illumina Inc
• Quest Diagnostics Inc
• Danaher Corp
• International Business Machines Corp
• Abbott Laboratories
• GE HealthCare Technologies Inc Common Stock
• Amgen Inc

TOP STRATEGIES USED BY THE KEY MARKET PLAYERS

Key players in the European personalised medicine market prioritise co-development of therapeutics and companion diagnostics to ensure synchronised regulatory approval and clinical adoption. They invest heavily in CE-marked, in vitro diagnostic compliant assay platforms that meet the stringent requirements of the EU’s IVDR framework. Companies form strategic alliances with national genomic initiatives and university hospitals to embed their technologies into public healthcare pathways. They deploy cloud-based bioinformatics solutions that comply with the General Data Protection Regulation while enabling cross-institutional data sharing. Firms also focus on workflow standardisation to accommodate Europe’s decentralised laboratory infrastructure. Additionally, they engage proactively with health technology assessment bodies to generate real-world evidence on clinical utility and cost-effectiveness. Continuous innovation in liquid biopsy, AI-assisted image analysis, and pharmacogenomic screening further strengthens their positioning in this highly regulated and evidence-driven market.

COMPETITION OVERVIEW

Competition in the European personalised medicine market is characterised by a tripartite dynamic involving global diagnostics leaders, innovative biotechnology firms, and public research institutions operating within a tightly regulated, publicly funded healthcare context. Unlike markets driven by commercial insurance, Europe’s adoption hinges on health technology assessment outcomes, national reimbursement decisions, and integration into statutory care pathways. Major players like Roche and Illumina compete not on price but on clinical validation, regulatory compliance, and interoperability with national genomic infrastructures. Niche innovators focus on specific biomarkers or therapeutic areas, often partnering with academic centres to generate real-world evidence. The entry barrier is high due to the In Vitro Diagnostic Regulation’s stringent clinical evidence requirements and the need for CE marking. Collaboration often outweighs direct rivalry, as seen in public-private partnerships under Horizon Europe and the 1+ Million Genomes Initiative.

TOP PLAYERS IN THE MARKET

• Roche Diagnostics was headquartered in Basel, Switzerland, which is a global leader in personalised medicine through its integrated portfolio of companion diagnostics and targeted therapies. In Europe, the company collaborates closely with national health systems to embed its diagnostic tests, such as the VENTANA PD L1 assay and cobas EGFR Mutation Test, into routine oncology pathways. Roche’s theranostic model, exemplified by drugs like trastuzumab and atezolizumab paired with specific biomarker tests, has become a benchmark for precision oncology. The company also expanded its partnership with the UK’s Genomics England to validate novel RNA-based signatures for early cancer detection.
• Illumina, with major European operations in Cambridge, England, an England Eindhoven, Netherlands, powers the genomic backbone of personalised medicine across the continent through its high-throughput sequencing platforms. Illumina actively supports regulatory harmonisation by participating in the European Commission’s In Vitro Diagnostic Regulation implementation working groups. Illumina introduced a CE-marked whole genome sequencing workflow optimised for clinical diagnostics, reducing turnaround time to under ten days. It also partnered with Sweden’s SciLifeLab to establish a reference centre for rare disease genomics.
• Qiagen is based in Hilden, Germany, which is a key eenabler of personalisedmedicine in Europe through its sample preparation, molecular diagnostics, and bioinformatics solutions. The company’s therascreen portfolio includes over 25 CE-marked companion diagnostic tests for oncology targets such as EGFR, KRAS, and BRAF, widely used in hospital laboratories across the EU. Qiagen’s strength lies in its modular approach, allowing integration with multiple sequencing and PCR platforms, which suits Europe’s fragmented laboratory landscape. It also expanded its collaboration with the Dutch Pharmacogenetics Working Group to support nationwide preemptive genotyping for drug safety.

MARKET SEGMENTATION

This research report on the European personalised medicine market has been segmented and sub-segmented based on categories.

By Product

• Personalised Medicine Diagnostics
• Personalised Medicine Therapeutics

By End Use

• Hospitals
• Diagnostic Centers
• Research & Academic Institutes
• Others

By Country

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe